Lifeward Strengthens Biomedical Portfolio with Oratech Acquisition, but Revenue Dips
Event summary
- Lifeward closed the Oratech acquisition, adding $6.5 million in cash and Protein Oral Delivery™ technology.
- First-quarter revenue declined 22% year-over-year to $3.9 million, driven by lower AlterG shipments.
- Operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies.
- ORMD-0801 oral insulin Phase 2 trial set to commence, managed by Oramed using transaction funds.
- ReWalk exoskeleton sales increased 11%, supported by expanded distribution and Medicare Advantage coverage.
The big picture
Lifeward's strategic pivot into biomedical innovation through the Oratech acquisition positions it to diversify beyond neurorehabilitation. However, the revenue decline highlights execution risks in scaling production and managing supply chain disruptions. The company's ability to balance growth in its core exoskeleton business with the development of high-value therapeutic platforms will be critical.
What we're watching
- Revenue Recovery
- Whether Lifeward can rebound from the 22% revenue decline by addressing supply chain constraints and securing AlterG orders.
- Clinical Trial Progress
- The pace at which the ORMD-0801 oral insulin Phase 2 trial advances, given its strategic importance to Lifeward's biomedical expansion.
- Operational Efficiency
- How sustained improvements in cash utilization and operating expenses will impact Lifeward's path to profitability.
Related topics